MedTrace Logo

Study to Evaluate the Efficacy and Safety of PAC-14028 Cream in Rosacea Patients

NCT02052999 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2014-02-03

No results posted yet for this study

Summary

The objective of this study is to determine the efficacy and safety of PAC-14028 1% cream of Amorepacific Corporation in patients with erythema-telangiectatic or papulopustular rosacea

Conditions

  • Erythematotelangiectatic Rosacea
  • Papulopustular Rosacea

Interventions

DRUG

PAC-14028 cream 1%

Participants received topical PAC-14028 cream 1% twice daily for 8 weeks

OTHER

Vehicle

Participants received topical Vehicle twice daily for 8 weeks

DRUG

Rozex gel 0.75%

Participants received topical Rozex gel 0.75% twice daily for 8 weeks

Sponsors & Collaborators

  • Amorepacific Corporation

    lead INDUSTRY

Principal Investigators

  • BeomJoon Kim, Professor · Department of Dermatology, Chungang University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-02-28
Primary Completion
2013-06-30
Completion
2013-08-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02052999 on ClinicalTrials.gov